Bloomberg News

Bayer Is Asked for More Xarelto Data by U.K. Health-Cost Agency

March 12, 2012

The U.K.’s health-cost agency asked Bayer AG (BAYN) for more information on the cost and effectiveness of the Xarelto blood-thinning drug in the treatment and prevention of clots in deep veins.

The data presented by the German drugmaker failed to show Xarelto offered value for money to the state-run National Health Service, the National Institute for Health and Clinical Excellence said today in an e-mailed statement. Bayer, health- care professionals and members of the public may now comment on the draft guidance, the agency said.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


Ebola Rising
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus